csph works-in-progress cost-effectiveness analysis of thromboprophylaxis for the prevention of...
TRANSCRIPT
![Page 1: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/1.jpg)
CSPH Works-in-Progress
Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous
Thromboembolism Associated with Major Urologic Cancer Surgery
Ye Wang, PhDCenter for Surgery and Public Health
August, 2014
![Page 2: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/2.jpg)
Presentation Overview
• Background
• PhD Dissertation Project
• Q & A
• Current Project at the Center
![Page 3: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/3.jpg)
Background – Disease Burden in the US
≤4cm
Venous thromboembolism (VTE):
• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
Annual incidence:
• > 250,000 clinically evident cases
• ≈ 25,000 deaths per year
Annual VTE-associated health care expenses:
• $1.9 to 4.2 billion
• > $ 5.0 billion in patients with cancers
Heit et al., Arch Intern Med 2008Spyropoulos et al., J Manag Care Pharm 2007
1/3 deaths occur in patients undergoing invasive procedures
Prevention of post-surgical VTE in patients with cancers
![Page 4: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/4.jpg)
Thromboprophylaxis for VTE
≤4cm
Thromboprophylaxis advocated for VTE according to
the ACCP:
ACCP = American College of Chest Physicians
Gould et al., Chest 2012
• Mechanical devicei.e., intermittent pneumatic compression
• Pharmacological agentsi.e., injectable anticoagulants
![Page 5: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/5.jpg)
Cost-Effectiveness of Thromboprophylaxis
≤4cm
Reduced incidence of VTE
Increased costs
Thromboprophylaxis
Complications
![Page 6: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/6.jpg)
Cost-Effectiveness Analysis
≤4cm
The economic, clinical and humanistic outcomes model:
Any disease management should aim to achieve balanced outcomes so that gains in one outcome would not sacrifice the opportunity gains in other outcomes and that the overall gains can be maximized and optimized.
Gunter, Am J Manag Care 1999
![Page 7: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/7.jpg)
Optimize the allocation of limited health care resources
Identify Measure Compare
Costs (e.g., resource consumption) Consequences (e.g., clinical or humanistic outcomes)
Cost-Effectiveness Analysis (continued)
Gunter, Am J Manag Care 1999
![Page 8: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/8.jpg)
Four types of cost-effectiveness analysis:
• Cost-minimization analysis
• Cost-effectiveness analysis
• Cost-benefit analysis
• Cost-utility analysis
Siegel et al., JAMA 1996
Recommended:• Quality-adjusted life
years (QALYs)
• Comparisons across various diseases and health interventions
Cost-Effectiveness Analysis (continued)
![Page 9: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/9.jpg)
Incremental Cost-Effectiveness Ratio (ICER)
ICER =
(CostsIntervention B – CostsIntervention A)
(EffectivenessIntervention B – EffectivenessIntervention A)
Direct CostsProceduresHospitalizationFollow-up Visits/TestsComplications
Indirect CostsLost WagesLost ProductivityCaregiving
SocietalCosts
BenefitsPhysical HealthMental Health
QALYs(calculated by utilities)
$
Non-SocietalCosts
Siegel et al., JAMA 1996
![Page 10: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/10.jpg)
Utility
Best possible health state
1
Worst possible health state
Death 0
Quality of Life (Utility)
0.4 Symptomatic Metastatic Prostate Cancer
0.2 Above the Knee Amputation
0.6 Severe Congestive Heart Failure
0.8 Disability after Hip Fracture
![Page 11: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/11.jpg)
QALYs
0.5
2 years
One QALY
Quality of Life (utilities)
![Page 12: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/12.jpg)
QALYs (continued)
Time
Intervention A
Death Death
Intervention B
QALYsGained
Quality of Life (utilities)
![Page 13: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/13.jpg)
✔
✗
Cost-Effectiveness Analysis
QALYsGained
QALYsLost
Increased Cost
Saves MoneyImproves Health
Costs MoneyWorsens Health
Saves MoneyWorsens Health
Cost MoneyImproves Health
?
?
Decreased Cost
Cost-Effectiveness Plane
![Page 14: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/14.jpg)
Willingness-to-Pay (WTP) Thresholds
Interpreting ICER(US Perspective)
Less than $50,000 per QALY gained Good Value
$50,000 to $100,000 per QALY gained Sometimes Good Value
Greater than $100,000 per QALY gained Rarely Good Value
![Page 15: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/15.jpg)
Decision Tree
Anticoagulation
No Event
Embolus
Bleed
Well
Dead
Disabled
Dead
Disabled
Fatal
Non-Fatal
Fatal
Non-Fatal
Recursive with multiple recurrencesUseful to short-term simulationsDifficult to assign utilities
![Page 16: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/16.jpg)
Markov Modeling
WELL DEADDISABLEDt
DEADDISABLEDWELL
Markov States
(Cycle 0)
(Cycle 1)
t+1
![Page 17: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/17.jpg)
Markov Modeling (continued)
WELL DEADDISABLEDt
DEADDISABLEDWELLt+1
Markov States
(Cycle 0)
(Cycle 1)
![Page 18: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/18.jpg)
Markov Modeling (continued)
WELL DEADDISABLEDt
DEADDISABLEDWELLt+1
Markov States
![Page 19: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/19.jpg)
Markov Modeling (continued)
WELL DEADDISABLEDt
DEADDISABLEDWELLt+1
Markov States
![Page 20: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/20.jpg)
Markov Modeling (continued)
WELL
DEADDISABLED
Events can recurSimulate over a lifetime horizonUtilities dependent on the cycle length
Markov States
![Page 21: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/21.jpg)
Markov Modeling (continued)
WELL
DEADDISABLED
Markovian Assumption
Markov States
“memory-less”
![Page 22: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/22.jpg)
PhD Dissertation Project
Part I. Patient-Reported Outcomes of Anticoagulants
• Psychometric properties (validation) of a medication adherence scale
• Evaluation of patients’ knowledge, satisfaction, and barriers to anticoagulant therapy
• …
Part II. Pharmacoeconomics of Anticoagulants• Utility evaluation for anticoagulant-related outcomes• Cost-effectiveness of oral anticoagulants for stroke
prevention in patients with atrial fibrillation
![Page 23: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/23.jpg)
Study 1
Utility evaluation for anticoagulant-related outcomes
![Page 24: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/24.jpg)
Study Design
Study design:• Cross-sectional patient survey
Sample size:• 100 patients
Inclusion criteria• ≥ 21 years old• Taking warfarin• Able to comprehend English or Chinese
Utility elicitation methods:• Standard gamble technique
![Page 25: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/25.jpg)
Health States
Seven long-term health states
• Well on warfarin• Well on dabigatran• Well on rivaroxaban• Major ischemic stroke• Minor ischemic stroke• Intracranial hemorrhage (ICH)• Current health state
Four short-term health states
• Transient ischemic attack (TIA)• Major extracranial hemorrhage (ECH)• Minor ECH• Myocardial infarction (MI)
![Page 26: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/26.jpg)
DescriptionsPublished literature
Preference assessment guidelines
Medical textbooks
Expert opinions
Gage et al., Arch Intern Med 1996Torrance, J Health Econ 1986Warrell et al., Oxford Textbook of Medicine 2003
Health State Descriptions
![Page 27: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/27.jpg)
Methods – SGAll health states were considered to be better than death:
Choice 1: Staying in the health state under evaluation for the rest of the patient’s life
p 1 - pChoice 2:
Standard Gamble Technique
![Page 28: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/28.jpg)
p 1 - p
Standard Gamble Technique (continued)
All health states were considered to be better than death:
![Page 29: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/29.jpg)
p 1 - p
Standard Gamble Technique (continued)
All health states were considered to be better than death:
Indifferent – utility value
![Page 30: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/30.jpg)
Results – A Brief Summary
Three best health states (mean ± SD)• Well on rivaroxaban (0.90 ± 0.15)• Well on warfarin (0.86 ± 0.17)• Well on dabigatran (0.83 ± 0.18)
Two health states worse than death (mean ± SD)• ICH (-0.09± 0.51)• Major ischemic stroke (-0.01 ± 0.53)
ICH = intracranial hemorrhage; SD = standard deviation.
![Page 31: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/31.jpg)
Study 2
Cost-effectiveness of oral anticoagulants for stroke prevention in patients with atrial fibrillation
![Page 32: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/32.jpg)
Methods – Treatment Options
Treatment options:
• Dabigatran 150 mg twice daily
• Dabigatran 110 mg twice daily
• Rivaroxaban once daily
• Adjusted-dose warfarin
![Page 33: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/33.jpg)
Base case
A hypothetical cohort of patients, who were:
• 65 years old
• Newly diagnosed with atrial fibrillation
• Having no contraindications to anticoagulation
![Page 34: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/34.jpg)
Model Information
Model type:• Markov model
Perspective:• The Singapore health care system
Horizon:• Lifetime
Cycle length:• Monthly
![Page 35: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/35.jpg)
Model Information
Outcomes:• Direct medical costs • QALYs• ICERs
Willingness-to-pay (WTP) threshold: • Singapore’s 2012 per-capita gross domestic product
(SGD 65,000/QALY)
Software: • TreeAge Pro Suite 2013 (TreeAge Software, Inc.,
Williamstown, MA)
![Page 36: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/36.jpg)
Clinical inputs:• Published clinical trials
Utility inputs:• Patient survey
Cost inputs:• Hospital databases
Model Inputs
![Page 37: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/37.jpg)
AF = atrial fibrillation, ECH = extracranial hemorrhage, ICH = intracranial hemorrhage, MI = myocardial infarction, RIND = reversible ischemic neurological deficit, TIA = transient ischemic attack.
Markov Model
![Page 38: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/38.jpg)
AF = atrial fibrillation, ECH = extracranial hemorrhage, ICH = intracranial hemorrhage, MI = myocardial infarction, RIND = reversible ischemic neurological deficit, TIA = transient ischemic attack.
Markov Model
![Page 39: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/39.jpg)
AF = atrial fibrillation, ICH = intracranial hemorrhage, RIND = reversible ischemic neurological deficit.
Markov Model (continued)
![Page 40: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/40.jpg)
Dominated
Eliminated by extended dominance
Results – Base-Case Analysis
Rivaroxaban versus Warfarin:ICER = SGD 36,231/QALY
![Page 41: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/41.jpg)
Results – One-Way Sensitivity Analysis
WTP threshold
![Page 42: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/42.jpg)
42
Results – Two-Way Sensitivity Analysis
![Page 43: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/43.jpg)
WTP threshold
Rivaroxaban and warfarin were cost-effective in 91.29% and 8.05% of the 10,000 iterations, respectively.
Results – Probabilistic Sensitivity Analysis
![Page 44: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/44.jpg)
Results – A Brief Summary
Base-case analysis• Rivaroxaban was the optimal choice compared to warfarin.
• The ICER of dabigatran 150 mg versus warfarin exceeded the WTP threshold.
• Dabigatran 110 mg was dominated by warfarin and rivaroxaban.
Probabilistic sensitivity analysis• Using a WTP threshold of SGD 65,000/QALY, rivaroxaban
and warfarin were cost-effective in 91.29% and 8.05% of the 10,000 iterations, respectively.
![Page 45: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/45.jpg)
Current Project at the CSPH
Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer Surgery
![Page 46: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/46.jpg)
Urologic Cancer in the US
≤4cm
National Caner Institute, Surveillance, Epidemiology, and End Results (SEER) Program 2014
Percentage of new cancer cases in the US in 2014
Prostate cancerBladder cancerKidney cancerTesticles cancerOthers
% Ranking14.00 1st 4.50 6th 3.80 8th 0.50 25th
77.20 -
![Page 47: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/47.jpg)
Effect of VTE in patients with urologic cancer
≤4cm
Lyman, Cancer 2011
Prevention of post-surgical VTE in patients with urologic cancer
![Page 48: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/48.jpg)
Thromboprophylaxis for VTE (continued)
≤4cm
Paucity of studies on VTE in the urologic literature
The ACCP recommendations for major urologic cancer
surgery are extrapolated from General Surgery
Ideal use of VTE prophylaxis remains unclear
ACCP = American College of Chest PhysiciansGould et al., Chest 2012
![Page 49: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/49.jpg)
Effectiveness of Thromboprophylaxis for VTE
≤4cm
Study design:• Retrospective data analysis (the Premier)
Inclusion criteria:• Adults (≥18 years old)• Admitted due to major urologic cancer surgery
Major urologic cancer surgery:• Radical prostatectomy• Radical nephrectomy• Partial nephrectomy• Radical cystectomy
![Page 50: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/50.jpg)
Research Question
Are thromboprophylaxis strategies cost-effective for the prevention of post-surgical VTE in patients with
urologic cancer?
![Page 51: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/51.jpg)
Methods – Treatment Options
Mechanical prophylaxis:• Intermittent pneumatic compression (IPC)
Pharmacological prophylaxis (injectable anticoagulants):• Low dose unfractionated heparin (LDUH)• Enoxaparin• Dalteparin• Tinzaparin• Fondaparinux• Argatroban
Comparator:• No prophylaxis
![Page 52: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/52.jpg)
Base case
A hypothetical cohort of patients, who are:
• 65 years old
• Undergoing major urologic cancer surgery
• Radical prostatectomy
• Radical cystectomy• Radical nephrectomy• Partial nephrectomy
![Page 53: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/53.jpg)
Model Information
Model type:• Markov model
Perspective:• Societal
Horizon:• Lifetime
Cycle length:• Monthly
![Page 54: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/54.jpg)
Model Information
Outcomes:• Direct & indirect medical costs • QALYs• ICERs
WTP threshold: • US$50,000/QALY-gained
Software: • TreeAge Pro Suite 2014 (TreeAge Software, Inc.,
Williamstown, MA)
![Page 55: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/55.jpg)
Clinical inputs:• Published literature
Utility inputs:• Published literature
Cost inputs:• The Perspective Database (Premier, Inc, Charlotte, NC)
Model Inputs
Direct medical costs:• Prophylaxis strategy• Complications (minor & major)
Indirect medical costs:• Health care for recovery
![Page 56: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/56.jpg)
CTPH = chronic thromboembolic pulmonary hypertension; DVT = deep vein thrombosis; IPC = intermittent pneumatic compression; LDUH = low dose unfractionated heparin; PE = pulmonary embolism; PTS = postthrombotic syndrome.
Markov Model
![Page 57: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/57.jpg)
CTPH = chronic thromboembolic pulmonary hypertension; DVT = deep vein thrombosis; PE = pulmonary embolism; PTS = postthrombotic syndrome.
Markov Model (continued)
![Page 58: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/58.jpg)
Further work (specific to this project)
Collect Data:• Costs• Utilities• Probabilities
Perform data analyses:• Base-case analysis• Sensitivity analyses (one-way, multiple-way and
probabilistic sensitivity analyses)
![Page 59: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/59.jpg)
Thanks to Mentor & Other Staff at the CSPH
Thank you!
Questions and Comments
Thank you!
Questions and Comments
![Page 60: CSPH Works-in-Progress Cost-Effectiveness Analysis of Thromboprophylaxis for the Prevention of Venous Thromboembolism Associated with Major Urologic Cancer](https://reader031.vdocument.in/reader031/viewer/2022013011/551c3f4e55034693488b4a32/html5/thumbnails/60.jpg)
Methods – Health state descriptions (cont’d)
• One side of your body is totally paralyzed and/or one side of your face droops.
• You are not able to walk or take care of yourself (e.g., bathing, dressing and feeding) without help.
• You are not able to perform most of your usual activities. • Your speech is unclear, and people have difficulty understanding
you. • You find it hard to write, but you may think clearly.
Major ischemic stroke
The descriptions for each health state consisted of one to six bullet points that described the health state’s important attributes.
An Example of health state descriptions